BP-2202

N/A

Report date: 2025/06/04 11:51:57

Base Information

Drug NameBP-2202
Drug Alias NameBP-2202BP2202
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy
Mechanisms of ActionB-cell maturation protein modulatorsT lymphocyte replacements
TargetsB-cell maturation protein
Therapy Area/IndicationsMultiple MyelomaNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryJapan
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesBrightpath Biotherapeutics Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBrightpath Biotherapeutics Co Ltd
Inactive CompaniesN/A
Active IndicationsMultiple Myeloma
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A